In the last 12 months, the only revenue segment was Medical Research and Development contributing AU$1.14m. The largest operating expense was General & Administrative costs, amounting to AU$2.26m (65% ...
Vectus Biosystems seeks to raise up to $10 million to help develop its treatment for fibrosis and high blood pressure. A company developing a treatment that may reverse debilitating fibrosis is ...
Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks Vectus Biosystems Limited has ...
• VB4-P5 – novel new chemical entity with potential to address significant unmet need in rare and large-market chronic kidney disease • The Program includes a novel new chemical entity, VB4-P5, along ...
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Vectus Biosystems Limited ( (AU:VBS)) has ...
Hosted on MSN
XORTX highlights new gout genetics research, reshapes board and clarifies financing as Vectus deal nears closing
The latest announcement is out from XORTX Therapeutics Inc ( (TSE:XRTX)). On December 31, 2025, XORTX Therapeutics highlighted newly published, independent genome-wide research showing more than 400 ...
Vectus Biosystems (VBS) has delivered a 87.500% change over the past year, with a 52-week range between 0.037 and 0.455. What Is the Average Daily Trading Volume of Vectus Biosystems (VBS)? The ...
Disclaimer: The following press release comes to you under an arrangement with Newsvoir. takes no editorial responsibility for the same.) New Delhi, Delhi, India (NewsVoir) Vectus Industries Limited ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results